Professor Jaakko Tuomilehto, Chief Scientific Officer (CSO), Dasman Diabetes has been listed among the 200 most cited researchers worldwide in Molecular Biology & Genetics.
Thomson Reuters has generated The World’s Most Influential Scientific Minds of 2015, a yearly list that encompasses leading researchers in various science disciplines that rank in the top 1% of highly cited papers based on field and publication year. Highly cited researchers were most recently identified based on the cited publications over an 11 year period, 2003-2013.
Prof. Tuomilehto has published over 1600 scientific peer-review articles and his publications have been cited over 110,000 times during his research career, holding a current h-index 153.
Before commencing the CSO position at Dasman Diabetes Institute, Prof. Tuomilehto was Professor Emeritus of Public Health of the University of Helsinki, Finland, Professor of Vascular Prevention at the Danube-University Krems in Krems, Austria and has also been associated with the Diabetes Prevention Unit of the Finnish National Institute for Health and Welfare in Helsinki and Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.
He has also worked as a Medical Officer for Cardiovascular and Metabolic Diseases in the WHO Regional Office for Western Pacific in Manila, Philippines, Professor of Public Health at the University of Kuopio, Finland and Research Professor at the National Public Health Institute in Helsinki, Finland.
Prof. Tuomilehto’s research topics stem from Diabetes, Cardiovascular System, Cardiology, Public, Environmental and Occupational Health, Controlled Clinical Trials and Lifestyle-related Health Research. His interests focus mainly on the epidemiology and prevention of diabetes, cancer, dementia, and cardiovascular disease.
As Principal Investigator of the WHO DIAMOND Project, Prof. Tuomilehto has conducted numerous studies in type 1 diabetes that have resulted in the mapping of type 1 diabetes prevalence worldwide. His landmark “Finnish Diabetes Prevention Study” was the first proper controlled trial showing that more than half of cases of type 2 diabetes can be avoided with lifestyle intervention. His studies have also led to several collaborative efforts for diagnosis of diabetes in the DECODE/DECODA (Diabetes Epidemiology-Collaborative analysis of Diagnostic Criteria in Europe/Asia), studies identifying susceptibility genes for type 1 & 2 diabetes and their associated traits, and generating European guidelines in “Diabetes and Cardiovascular Disease Guideline” task force.
Prof. Tuomilehto is an Editorial Board member and Assistant Editor in several scientific journals, and currently serves as the Editor-in-Chief of Primary Care Diabetes.
Prof. Tuomilehto has received many prestigious scientific awards, including:
ADA Kelly West Award and ADA Harold Rifkin Award, USA
UNESCO/Hellmut Mehnerst Award, Dresden, Germany
EASD Camillo Golgi Award, Budapest, Hungary
Sheik Hamdan International Diabetes Award, Dubai
ESC Geoffrey Rose Award, Paris, France
Folksam Prize of the Karolinska Institute, Stockholm, Sweden
AHA Fredrick H Epstein Award, Washington, USA.